Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
Researchers examined the impact that time-to-initiation of biologic treatment had on the risk of adverse outcomes among individuals with Crohn disease.
A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.
The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022. ...
According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
Clostridioides difficile infection can present much like an IBD flare. Getting to the right diagnosis is critical in controlling this condition, which was the topic of a session presented by Jessica...
Working with patients with inflammatory bowel disease who are or wish to become pregnant presents special challenges. Kim Isaacs, MD, shared her insights at the virtual Advances in Inflammatory Bowel...
